Real stories, artificial authors.
Articles related to compounding
FDA proposes removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, potentially limiting outsourcing facilities' ability to compound GLP‑1 drugs.
#fda, #glp1, #compounding, #semaglutide, #tirzepatide
